Understanding familial risk of pancreatic ductal adenocarcinoma
- PMID: 38609521
- PMCID: PMC11660179
- DOI: 10.1007/s10689-024-00383-2
Understanding familial risk of pancreatic ductal adenocarcinoma
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease that is the result of an accumulation of sequential genetic alterations. These genetic alterations can either be inherited, such as pathogenic germline variants that are associated with an increased risk of cancer, or acquired, such as somatic mutations that occur during the lifetime of an individual. Understanding the genetic basis of inherited risk of PDAC is essential to advancing patient care and outcomes through improved clinical surveillance, early detection initiatives, and targeted therapies. In this review we discuss factors associated with an increased risk of PDAC, the prevalence of genetic variants associated with an increased risk in patients with PDAC, estimates of PDAC risk in carriers of pathogenic germline variants in genes associated with an increased risk of PDAC. The role of common variants in pancreatic cancer risk will also be discussed.
Keywords: Cancer; Genetics; Pancreas; Risk; Surveillance.
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Conflict of interest statement
Conflict of Interest
Dr. Nicholas Roberts is a Section Editor (Cancer Genomics) for Annals of Pancreatic Cancer.
Similar articles
-
Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.JAMA Oncol. 2023 Jul 1;9(7):955-961. doi: 10.1001/jamaoncol.2023.0806. JAMA Oncol. 2023. PMID: 37200008 Free PMC article.
-
BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.Cancer. 2014 Jul 1;120(13):1960-7. doi: 10.1002/cncr.28662. Epub 2014 Apr 15. Cancer. 2014. PMID: 24737347 Free PMC article.
-
Germline Pathogenic Variants in Patients with Pancreatic Ductal Adenocarcinoma and Extra-Pancreatic Malignancies: A Nationwide Database Analysis.Mod Pathol. 2025 May;38(5):100709. doi: 10.1016/j.modpat.2025.100709. Epub 2025 Jan 9. Mod Pathol. 2025. PMID: 39793706
-
Germline Testing for Individuals with Pancreatic Adenocarcinoma and Novel Genetic Risk Factors.Hematol Oncol Clin North Am. 2022 Oct;36(5):943-960. doi: 10.1016/j.hoc.2022.07.008. Hematol Oncol Clin North Am. 2022. PMID: 36265992 Review.
-
ATM Serine/Threonine Kinase and its Role in Pancreatic Risk.Genes (Basel). 2020 Jan 17;11(1):108. doi: 10.3390/genes11010108. Genes (Basel). 2020. PMID: 31963441 Free PMC article. Review.
Cited by
-
Integrative genomic and bioinformatic prioritization of drug repurposing candidates for prostate cancer.BMC Pharmacol Toxicol. 2025 Aug 5;26(1):145. doi: 10.1186/s40360-025-00983-3. BMC Pharmacol Toxicol. 2025. PMID: 40764606 Free PMC article.
References
-
- (2023) SEER*Explorer: An interactive website for SEER cancer statistics. vol. August 3, 2023, National Cancer Institute, pp SEER Incidence Data, November 2022 Submission (1975-2020), SEER 22 registries (excluding Illinois and Massachusetts). Expected Survival Life Tables by Socio-Economic Standards.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical